Local view for "http://purl.org/linkedpolitics/eu/plenary/2011-02-16-Speech-3-215-000"
| Predicate | Value (sorted: default) |
|---|---|
| rdf:type | |
| dcterms:Date | |
| dcterms:Is Part Of | |
| dcterms:Language | |
| lpv:document identification number |
"en.20110216.11.3-215-000"2
|
| lpv:hasSubsequent | |
| lpv:speaker | |
| lpv:spokenAs | |
| lpv:translated text |
"−
I agree with the Matias report’s assertion that patients must have absolute certainty as to the quality of the medicines they take. From studies it is clear that the use of falsified medicines is so dangerous for patients that it puts lives at risk: it is therefore right to consider falsification to be a criminal act warranting the adoption of a strong stance by the European Union.
Hence my support for the points contained in the report, namely: that there should be clear definitions relating not only to the scope, but also to the different actors in the supply chain, in order to clarify their roles and responsibilities; that sanctions should be equivalent to those applied for illegal acts involving narcotics; and that there should be enhanced transparency and regulation of medicine sales on the Internet, thereby enabling consumers to distinguish between illegal operators and online pharmacies.
Today, more than ever, active collaboration between different national and international agencies is emerging as a key factor in a more effective system to combat pharmaceutical falsification. Such a system can ensure appropriate monitoring not only of pharmaceutical falsification within the European Union but also of falsified medicines exported to third countries, the numbers of which continue to increase. The guiding principle should be patient welfare in all cases."@en1
|
Named graphs describing this resource:
The resource appears as object in 2 triples